Department

Potential of low-light therapy for dry AMD

Trial shows effectiveness of the Valeda Light Delivery System photobiomodulation platform.

The gene therapy ATSN-101 has demonstrated safety and shown signals of efficacy in restoring vision in Leber congenital amaurosis.

A Phase III trial is on deck for the oral Ref-1 inhibitor APX3330 after a Phase IIb study showed a potential benefit.

Interim results from Phase I trial of OTX-TKI, a bioresorbable hydrogel platform using a tyrosine kinase inhibitor.

A look at UBX1325, a small-molecule B-cell inhibitor that targets the proteins senescent cells feed on for survival.

A closer look at the extension study of GB-102 for treatment of neovascular age-related macular degeneration.

Trial shows safety of a biosynthetic patch inserted in a subretinal bleb in an outpatient procedure.

The IgG antibody fragment ANX007 aims to disrupt the cascade that leads to geographic atrophy at the initiating molecule.

The plasma kallikrein inhibitor is being investigated to treat diabetic macular edema that doesn’t respond to anti-VEGF therapy.

DAVIO Phase I results of EYP-1901 show reduced treatment burden in age-related macular degeneration.